Bryan Gilburg - China

“The TFDA announced several key updates at the virtual meeting including a new RA certification program and the potential use of third-party review bodies.

Sayoomporn (Noi) Suwannabot

General Manager, Asia Actual Thailand

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sign Up For Our Newsletter to Stay Informed

Sign Up

Thai FDA Improves Medical Device Application Process

Published on: June 28th, 2023

New Expedited Regulatory Applicant Certification Program and Priority Track Pathways Aim to Speed Up the Approval Process

In a meeting on June 19, 2023, the Thai Food and Drug Administration (TFDA) outlined new measures to improve the medical device registration application program.

The six key initiatives discussed included:

  1. New Expedited Review for Certified Applicants: The TFDA Foundation will organize a training course to certify the competency of medical device registration applicants (RAs). Once an RA has completed the training, they will be given a certification number which can use when submitting applications, initiating a faster review process. They expect to start the certification course sometime in August 2024. Asia
  2. Pre-screening is Now Optional: As of July 1, 2023, the pre-screening step in the medical device registration applications process will be made optional. This change will speed up the process for applicants by at least seven days. Applicants will have the option to undergo the pre-screening process or proceed directly with submitting applications.
  3. Resubmission of Rejected Applications: From June 19, 2023, applicants can resubmit previously rejected applications and the TFDA will resume the review process from where it was discontinued. Applicants will no longer have to restart the application with a different reviewer, which will make the resubmission process more efficient and seamless and reduce overall review times. A new application fee will be required to re-submit, but this cost is nominal (approximately US$70 for risk class 1 and US$370 for risk class 2 or 3 and US$667 for risk class 4).
  4. New Priority Review Track Established for Devices with Urgent Public Need: As of June 19, 2023, registration applications for specific types of medical devices will be able to opt for a priority track that will speed up the review process for critical medical devices. Applicants who use this route must be able to prove the device’s urgent public need. This option will be available for registrations of medical devices that are:
    • Related to urgent public health problems, such as pandemics
    • Life-saving tools
    • Requested by agencies or non-profit organizations
    • Renewals of previously approved devices that are urgently needed
  5. Submission Strategy Planning: Starting approximately January 2024, the TFDA will encourage applicants to send their submission strategy to TFDA in advance. This will allow TFDA officials to anticipate their workload and better plan their resources accordingly, further streamlining the application management process. Asia Actual expects that this option will be exercised mostly by large multinationals with extensive product portfolios to manage.
  6. Registered Certification Body Review: The TFDA also announced that it is looking at options for working with external expert bodies. While this option is still in the proposal stage, these entities could potentially act like notified bodies (NBs) or conformity assessment bodies (CABs) to provide an expedited review option for an additional fee. We expect this new program to be similar to third-party review systems in Europe, Japan, Korea, or Malaysia. Asia Actual will continue to monitor developments on this issue due to its potential impact on the cost and time for market access in Thailand.

Stay Up to Date with Us

As always, Asia Actual is committed to keeping abreast of these latest developments to monitor how they’ll affect our clients’ ability to more quickly and effectively apply for medical device registration in Thailand.

Our Bangkok office is staffed by experienced, bilingual regulatory commercial professionals.  Contact us for more information or to explore your market access options in Thailand.


Asia Actual is a regulatory consulting company focused on helping manufacturers grow sales in challenging Asia markets through device registration, independent license holding, direct fulfillment, and a variety of sales channel support services.

Blog Posts

Australia SaMD Transition Deadline

Australia’s SaMD Regulatory Deadline

Beginning on November 1st, 2024, Australia's Therapeutic Goods Administration will implement new rules surrounding software as a medical device (SaMD). While some SaMD will require additional regulatory requirements, other SaMD will be exempted from some, or excluded completely, from the new regulations.
Thai FDA Documentation Exemptions for Concise and Full Regulatory Pathways

Thai FDA Regulatory Documentation Exemptions

March 12, 2024: the Thai FDA released draft guidance updating the list of required documentation for Full and Concise Evaluation. For manufacturers registering a medical device in Thailand, certain documents are no longer required.
Hong Kong MDD adds Singapore HSA to Reference Country List

Hong Kong MDD Adds Singapore as Reference Country

Starting April 2nd, 2024, the Hong Kong Medical Device Division (MDD) accepts, on a regular basis, the marketing approvals obtained from the the Health Sciences Authority (HSA) of Singapore as a support of compliance of medical device to the "Essential Principles of Safety and Performance of Medical Devices" (Technical Reference: TR-004) under MDACS.